Want to see XRAY full AI Analyst Report?
XRAY Stock Chart & Stats
$12.51
-$0.04(-0.21%)
At close: 4:00 PM EST
$12.51
-$0.04(-0.21%)
Day’s Range― - ―
52-Week Range$9.41 - $17.09
Previous CloseN/A
Volume461.38K
Average Volume (3M)5.91M
Market Cap
$2.36B
Enterprise Value$4.15B
Total Cash (Recent Filing)$190.00M
Total Debt (Recent Filing)$2.33B
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Jul 30, 2026EPS Estimate
0.35Next Dividend Ex-DateN/A
Dividend Yield5.61%
Share Statistics
EPS (TTM)-3.15
Shares Outstanding200,326,680
10 Day Avg. Volume7,024,227
30 Day Avg. Volume5,907,296
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.70
Price to Sales (P/S)0.62
P/FCF Ratio21.91
Enterprise Value/Market Cap1.76
Enterprise Value/Revenue1.13
Enterprise Value/Gross Profit2.30
Enterprise Value/Ebitda-32.68
Forecast
1Y Price Target
$13.55Price Target Upside8.31% Upside
Rating ConsensusHold
Number of Analyst Covering13
EPS Forecast (FY)1.42
Revenue Forecast (FY)$3.59B
Bulls Say, Bears Say
Bulls Say
Diversified Revenue Mix & Recurring ConsumablesDentsply Sirona's mix of high‑frequency consumables and capital equipment creates durable recurring revenue. An installed base of devices drives repeat consumable, service and software purchases, improving revenue visibility and supporting long‑term cash flows independent of single equipment cycles.
Positive Cash GenerationSustained positive operating and free cash flow provides financial flexibility to fund restructuring, R&D and debt reduction. Even with near‑term profit volatility, cash generation supports execution of the return‑to‑growth plan and reduces reliance on external financing over the medium term.
Innovation & Digital Product RolloutNew diagnostics (AI), dental MRI clearance and updated endodontic and digital systems strengthen differentiation in a structural shift toward digital dentistry. These product launches can expand high‑margin software/service attach rates and drive longer‑term adoption across the installed base.
Bears Say
Persistent UnprofitabilityConsistent trailing losses and a ~-17% net margin indicate operating and mix issues that erode equity and impede reinvestment. Until margins sustainably recover, earnings will remain constrained, limiting retained earnings and long‑term return generation for shareholders.
Elevated LeverageA markedly higher debt-to-equity ratio reduces financial flexibility and raises refinancing and covenant risk during cyclical softness. Elevated leverage constrains capital allocation, making it harder to invest in growth or withstand prolonged demand weakness without additional deleveraging.
Structural Margin Headwinds & DestockingSustained margin compression from tariffs, unfavorable mix and distributor destocking reduces operating leverage and free cash conversion. Pending inventory sell‑through and ongoing tariff exposure create prolonged pressure on margins and cash, delaying deleveraging and return‑to‑profit goals.
DENTSPLY SIRONA News
XRAY FAQ
What was DENTSPLY SIRONA’s price range in the past 12 months?
DENTSPLY SIRONA lowest stock price was $9.40 and its highest was $17.09 in the past 12 months.
What is DENTSPLY SIRONA’s market cap?
DENTSPLY SIRONA’s market cap is $2.36B.
When is DENTSPLY SIRONA’s upcoming earnings report date?
DENTSPLY SIRONA’s upcoming earnings report date is Jul 30, 2026 which is in 19 days.
How were DENTSPLY SIRONA’s earnings last quarter?
DENTSPLY SIRONA released its earnings results on May 05, 2026. The company reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.278 by -$0.008.
Is DENTSPLY SIRONA overvalued?
According to Wall Street analysts DENTSPLY SIRONA’s price is currently Undervalued.
Does DENTSPLY SIRONA pay dividends?
DENTSPLY SIRONA pays a Quarterly dividend of $0.16 which represents an annual dividend yield of 5.61%. See more information on DENTSPLY SIRONA dividends here
What is DENTSPLY SIRONA’s EPS estimate?
DENTSPLY SIRONA’s EPS estimate is 0.35.
How many shares outstanding does DENTSPLY SIRONA have?
DENTSPLY SIRONA has 200,326,680 shares outstanding.
What happened to DENTSPLY SIRONA’s price movement after its last earnings report?
DENTSPLY SIRONA reported an EPS of $0.27 in its last earnings report, missing expectations of $0.278. Following the earnings report the stock price went down -2.023%.
Which hedge fund is a major shareholder of DENTSPLY SIRONA?
Currently, no hedge funds are holding shares in XRAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DENTSPLY SIRONA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$13.55 (8.31% Upside)
$13.55 (8.31% Upside)
Blogger Sentiment
Bullish
XRAY Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $515.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 18.6%
Last 30 Days ▲ 18.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.24%
12-Months-Change
Fundamentals
Return on Equity
-41.21%
Trailing 12-Months
Asset Growth
-13.57%
Trailing 12-Months
Company Description
DENTSPLY SIRONA
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as well as CEREC, a full-chairside economical restoration of esthetic ceramic dentistry offering. The Essential Dental Solutions segment provides motorized endodontic handpieces, files, sealers, irrigation needles, and other tools for root canal procedures; restorative products; curing light and dental diagnostic systems; ultrasonic scalers and polishers; and dental anesthetics, prophylaxis paste, dental sealants, and impression materials. The Orthodontic and Implant Solutions segment offers SureSmile, a clear aligner solution that includes whitening kits and retainers; VPro, a high frequency vibration technology device; SureSmile Simulator; DS Core platform, which creates 3D visualization of patient outcomes; dental implant products; digital dentures; crown and bridge porcelain products; bone regenerative and restorative solutions; treatment planning software; educational programs; custom abutments; tapered immediate load screws; regenerative bone growth factor; artificial teeth; and precious metal dental alloys. The Wellspect Healthcare segment offers medical devices, including catheters for urinary retention and advanced irrigation systems to help people suffering from chronic or severe constipation. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina.
XRAY Company Deck
XRAY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced mix of encouraging operational and financial actions alongside notable near-term challenges. Positives include improved operating cash flow, active deleveraging (≈$79–$80M debt retired), early cost savings (≈$20M OpEx reduction in Q1) and meaningful innovation launches (AI diagnostic aid with ~46% sensitivity improvement, dental MRI clearance, new endodontic tools). Management also maintained full-year guidance and highlighted distributor expansion and early commercial traction. Offsetting these are material constant-currency revenue declines (Q1 cc sales down 6.7%, down 4.5% excluding one-time items), significant margin compression (adjusted EBITDA down 430 bps; gross profit down 560 bps), softness in several key segments (OIS, EDS, IPS, CTS), tariff-related margin pressure, distributor destocking, and an expected ~$30M inventory sell-through headwind later in the year. Given the roughly balanced set of meaningful positives (cash, cost saves, innovation, distribution) and negatives (sales declines, margin pressure, macro/timing risks), the overall tone is cautiously constructive but realistic about near-term headwinds.View all XRAY earnings summariesXRAY Net sales Breakdown
15.71% Equipment & Instruments
12.45% CAD/CAM
39.92% Essential Dental Solutions
6.17% Orthodontics
16.93% Implants & Prosthetics
8.83% Wellspect Healthcare
XRAY Stock 12 Month Forecast
Average Price Target
$13.55
▲(8.31% Upside)
Technical Analysis
Ownership Overview
0.83% Insiders
32.56% Mutual Funds
0.03% Other Institutional Investors
43.71% Public Companies and
Individual Investors